Patient P-01883
Synthetic patientNBL-101 · Day 108 · 65–74 · M · baseline S16Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
17%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S16
- Day 17 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 17.
Primary contributors, last 14 days
- Treatment adherence+4
- Toxicity+4
- GI instability+3
- Inflammatory activity-2
- Nutritional resilience+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion20.7/100
improving · -4.0 vs previous 14 d
Toxicity
Blood19.4/100
worsening · +8.5 vs previous 14 d
Sleep quality
Wearable67.4/100
stable · +1.4 vs previous 14 d
Energy level
Daily log6.2/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log4.2/10
worsening · +0.3 vs previous 14 d
Steps
Wearable2,723
improving · +191 vs previous 14 d
Adherence
Companion93.9 %
stable · +1.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 85 from the failing basin, 3 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- Nothing clearly counter-productive in the record.
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Alcohol+0.9no signal · 26%
- Simple carbohydrates-0.4no signal · 15%
- Insoluble fibre-0.2no signal · 15%
- Dietary fat load-0.1no signal · 15%
- Spicy / capsaicin-0.1no signal · 15%
- Histamine load0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↑20
- Wearable2,723 steps/day
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 3.9 · butyrate capacity 70/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 66 ms
- Sleep
- 7.8 h
- Steps
- 3,289
- Resting HR
- 65 bpm
Daily log: GI score 21, nutritional resilience 64, adherence 94.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01766 | 38% | S05 | AD-05 | no change | 90 |
| P-01804 | 30% | S19 | AD-05 | improved | 61 |
| P-01541 | 28% | S09 | AD-05 | no change | 43 |
| P-01677 | 48% | S05 | BR-03 | no change | 86 |
| P-01329 | 42% | S08 | BR-03 | improved | 79 |
| P-01495 | 34% | S07 | BR-03 | improved | 85 |
| P-01689 | 29% | S13 | BR-03 | no change | 50 |
| P-01654 | 35% | S08 | CR-01 | improved | 85 |
| P-01430 | 28% | S05 | CR-01 | improved | 54 |
| P-01479 | 44% | S15 | DT-01 | improved | 84 |
| P-01855 | 42% | S04 | DT-01 | improved | 73 |
| P-01724 | 35% | S10 | DT-01 | improved | 63 |